Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting
Open Access
- 15 September 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (18), 4743-4747
- https://doi.org/10.1158/1078-0432.ccr-19-4035
Abstract
The 2019 Accelerating Anticancer Agent Development (AAADV) Workshop assembled a panel of experts for an in-depth discussion session to present "Novel Therapeutic Interventions Early in the Disease Trajectory." The panel reviewed the limitations of evaluating investigational cancer therapeutics solely in advanced metastatic and relapsed/refractory disease settings, and recommended strategies for drug evaluation earlier in the disease course, including in the first line in combination with standard chemotherapy and in the maintenance and neoadjuvant disease settings. Advantages of earlier drug evaluation were discussed, including expanding the population of evaluable patients, earlier response assessment via surrogate endpoints, earlier clinical benefit in the disease course, tailoring of therapies based on response, and furthering our understanding of biomarker-driven therapies.Keywords
Funding Information
- AAADV
This publication has 16 references indexed in Scilit:
- Accelerated vs. regular approval: Lessons learned from U.S. FDA oncology approvals.Journal of Clinical Oncology, 2018
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialThe Lancet Oncology, 2018
- Abstract PD6-14: Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancerCancer Research, 2018
- Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trialThe Lancet Gastroenterology & Hepatology, 2017
- DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trialnpj Breast Cancer, 2017
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast CancerNew England Journal of Medicine, 2017
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or BothNew England Journal of Medicine, 2017
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast CancerNew England Journal of Medicine, 2015
- Modul–A Multicentre Randomised Clinical Trial of Biomarker-Driven Therapy for the 1St-Line Maintenance Treatment of Metastatic Colorectal Cancer (Mcrc): a Signal-Seeking ApproachAnnals of Oncology, 2014
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012